#	Pagina
attuale pagina	/open-h2020/projects/207917/index.html

Opendata, web and dolomites

CureTheCloves SIGNED

PIK3CA inhibition in patients with the CLOVES syndrome

Total Cost €

EC-Contrib. €

Partnership

Views

CureTheCloves project word cloud

Explore the words cloud of the CureTheCloves project. It provides you a very rough idea of what is the project "CureTheCloves" about.

molecular drug disorder purpose vascular pik3ca dramatically epidermal mutation skeletal fashion effect survival spinal mosaic lipomatous gain disease function severe syndrome deformation cloves malformations scoliosis patients congenital understand rare accede designation overgrowth poor proof nevi orphan grant genetic outcome

Project "CureTheCloves" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITE PARIS DESCARTES Organization address address: RUE DE L ECOLE DE MEDECINE 12 city: PARIS CEDEX 06 postcode: 75270 website: www.univ-paris5.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Total cost	148˙750 €
EC max contribution	148˙750 € (100%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2016-PoC
Funding Scheme	ERC-POC
Starting year	2017
Duration (year-month-day)	from 2017-02-01 to 2018-07-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITE PARIS DESCARTES UNIVERSITE PARIS DESCARTES Organization address address: RUE DE L ECOLE DE MEDECINE 12 city: PARIS CEDEX 06 postcode: 75270 website: www.univ-paris5.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS CEDEX 06)	coordinator	148˙750.00

Map

Project objective

The Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, Scoliosis/Skeletal and Spinal (CLOVES) syndrome is a genetic disorder due to a gain of function mutation of the PIK3CA in a mosaic fashion. This rare condition is associated with severe deformation and poor survival. We identified a new drug able to dramatically improve the outcome of patients with this rare disease. The purpose of the Proof of Concept grant is to better understand the molecular effect of this drug and to rapidly accede to Orphan drug designation.

Publications

List of publications.
year	authors and title	journal	last update
2018	Quitterie Venot, Thomas Blanc, Smail Hadj Rabia, Laureline Berteloot, Sophia Ladraa, Jean-Paul Duong, Estelle Blanc, Simon C. Johnson, ClÃ©ment Hoguin, Olivia Boccara, Sabine Sarnacki, Nathalie Boddaert, Stephanie Pannier, Frank Martinez, Sato Magassa, Junna Yamaguchi, Bertrand Knebelmann, Pierre Merville, Nicolas Grenier, Dominique Joly, ValÃ©rie Cormier-Daire, Caroline Michot, Christine Bole-Feysot, Arnaud Picard, VÃ©ronique Soupre, Stanislas Lyonnet, Jeremy Sadoine, Lotfi Slimani, Catherine Chaussain, CÃ©cile Laroche-Raynaud, Laurent Guibaud, Christine Broissand, Jeanne Amiel, Christophe Legendre, Fabiola Terzi, Guillaume Canaud Targeted therapy in patients with PIK3CA-related overgrowth syndrome published pages: 540-546, ISSN: 0028-0836, DOI: 10.1038/s41586-018-0217-9	Nature 558/7711	2019-06-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CURETHECLOVES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CURETHECLOVES" are provided by the European Opendata Portal: CORDIS opendata.